Thrombolytic therapy in review.
The use of thrombolytic agents for both coronary and noncoronary indications is a rapidly progressing field. There has been substantial debate over which disease processes ultimately benefit from the use of thrombolytic agents. In addition, many recent studies have focused on comparing different thrombolytic agents and dosing regimens in an attempt to gain optimal therapeutic benefit with minimal risk. This paper discusses the current status of thrombolytic therapy for coronary artery disease, pulmonary embolus, peripheral vascular thrombosis, and cerebrovascular infarction.
Thomas
S H
SH
Department of Emergency Medicine, East Carolina University School of Medicine/University Medical Center of Eastern Carolina, Greenville, North Carolina 27858-4354.
Shepherd
S M
SM
Allison
E J
EJ
D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D000075202:Contraindications; D003327:Coronary Disease / Q000188:drug therapy*; D004630:Emergencies; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000379:methods*
D005343:Fibrinolytic Agents